Risk groups with increased vulnerability for influenza complications such as pregnant women, persons 15 with underlying illnesses as well as persons who contact them, such as health care workers, are currently 16
Introduction

34
Seasonal influenza causes a substantial number of symptomatic infections, hospitalisations and fatalities, 35 especially in young children, the elderly and people with underlying illnesses [1] . The Superior Health 36
Council of Belgium recommends giving priority to immunizing people at increased risk of influenza 37 complications, namely people living in institutions, people with underlying illnesses and the elderly (>65 38 years). Furthermore, health care workers (HCWs), pregnant women in the 2 nd and 3 rd trimester of 39 pregnancy, the general population between 50 and 64, and poultry and pig farmers and their household 40 members, have priority over the general population [2] . Prioritization is important, because the demand 41 for influenza vaccines has surpassed supply in recent years [3] . Although these recommendations were 42 based on the medical literature, their potential cost-effectiveness was largely unknown. Also, doubts 43 have been expressed about the usefulness of influenza vaccination in view of uncertainties related to 44 season-specific effectiveness in at-risk groups [4] . Therefore, up to date information on the cost-45 effectiveness of vaccinating these risk groups, may improve the prioritisation and acceptability of 46 seasonal influenza vaccines. In this paper, we evaluate the cost-effectiveness of increasing seasonal 47 influenza vaccine uptake in (1) pregnant women in their 2 nd and 3 rd trimester, (2) HCWs and (3) people 48 with underlying illnesses. Currently these groups have relatively low vaccine uptake [3] , despite the 49 above recommendations. Cost-effectiveness analyses of influenza vaccination of the elderly are 50 presented elsewhere in combination with childhood vaccination options using a dynamic transmission 51 model [3] . We did not consider here the specific risk group of poultry and pig farmers, because the 52 rationale for their vaccination (recombination of viruses in their work environment with potential risk to 53 the general population) requires a different modelling approach. 54
The cost-effectiveness of vaccinating pregnant women [5] [6] [7] , HCWs [8] [9] [10] [11] and people with underlying 55 illnesses [12] [13] [14] [15] [16] has been evaluated before in other countries, but the results depended strongly on 56 assumed vaccine efficacy. In this study, we use the most up to date estimates [17] , and consider the 57 potential impact of influenza vaccination beyond the target group. Vaccination during pregnancy has the 58 potential to reduce foetal death through avoided maternal mortality, and confers vaccine-induced 59 immunity to the neonate [18] . In previous cost-effectiveness analyses, these potential effects were not 60 [5, 7] or only partially [6] accounted for. Vaccinating HCWs was also shown to have an effect on the 61 patients they contact [19, 20] . This could be of particular importance for institutionalised or hospitalised 62 patients and the elderly in general, and is therefore also considered in our analyses. 63
Material and methods
65
Decision analytic model 66
Since the groups of pregnant women, HCWs and people with underlying illness are relatively small in 67
Belgium and are not core transmitter groups for the influenza virus, the cost-effectiveness of their 68 vaccination can be analysed using a static model [21] . For each risk group, a decision tree model was 69 developed in the R software. (R development Core Team, 2012, http://www.R-project.org). The general 70 structure is displayed in Figure 1 and model parameters are listed in Direct medical costs and QALY losses associated with these outcome categories were included in order 79 to compare the costs and QALYs of current with increased vaccine uptake scenarios (up to 50% (40% for  80 persons with underlying illnesses)) [1] . A health care payer perspective was used. Costs and non-fatal 81 health outcomes were not discounted because of the short analytical time horizon (one year). Future 82 life-years lost due to influenza-attributable mortality were discounted at an annual rate of 1.5%, in 83 accordance with Belgian guidelines [22] . 84
We assumed the vaccine is offered to pregnant women, on average in calendar week 47 (i.e. mid-85 November). We assumed also a 4-week delay before vaccinees benefit from vaccine protection. Hence, 86 costs and QALY losses were included for infections occurring between calendar week 51 and 25 87 (assumed end of the influenza season), by using a partial attack rate in the model (84% of the yearly ILI 88 cases occurs in that time window). According to the Belgian guidelines, pregnant women should receive 89 an influenza vaccine during the second or third trimester of their pregnancy, implying the average 90 delivery date of pregnant vaccine recipients is in calendar week 7 (assuming uniformly distributed 91 deliveries over the year and vaccination in calendar week 47). It is assumed that when the pregnant 92 mother dies due to influenza, so does the foetus. Therefore, to account for fatalities in the period leading 93 up to calendar week 7, the discounted expected life years lost of both the mother and her unborn child 94 are summed to calculate the associated cost-effectiveness ratios. From calendar week 7 until week 25, 95 infants can be assumed to be exposed to an autonomous risk of acquiring an influenza infection (one 96 third of the annual attack rate in the infant (<1 year) age category 
Uncertainty, variable importance and sensitivity analysis 128
Where appropriate, uncertainty around the input parameters was specified as probability distributions 129 (Table 1, [24] ). For the hospitalisation and case-fatality ratios, the number of successes and the number 130 of failures from the beta distribution are based on the predictions obtained from different selected 131 "best" regression models (see above). Model uncertainty was taken into account by randomizing with 132 equal probability between selected regression models for the different outcome measures. To assess the 133 uncertainty of the cost-effectiveness results, we conducted Monte-Carlo sampling with 10,000 draws 134 taken from the joint input distribution, assuming independence of the uncertain input variables (i.e. 135 probabilistic sensitivity analysis). 136
The relative influence of each of the uncertain parameters was investigated by fitting multiple linear 137 regression models with as covariates all standardized uncertain input variables and as response the 138 incremental costs, the incremental QALYs gained and the net benefits. The net benefit was calculated by 139 subtracting the incremental costs from the QALYs gained valued at €35,000 per QALY. In Belgium there is 140 no official willingness to pay threshold to obtain gains in (quality-adjusted) life years, but €35,000 is 141 about the Gross Domestic Product per capita. The amount of GDP per capita has been put forward by 142 the World Health Organization as representing the costs per QALY gained of a 'very cost-effective' 143 strategy [25] . The larger the absolute value of the regression coefficients, the more important the 144 uncertain parameter is in determining the response (incremental costs, QALYs and net benefits). 145
Probabilistic sensitivity analysis was repeated for different key model assumptions regarding clinical 146 protection against influenza transferred from mother to child, the number of influenza cases caused in 147 patients through contacts with health care workers, and life expectancy of people with underlying 148 illnesses relative to that of the general population. An important question regarding implementation is 149 whether we can assume zero marginal administration costs for vaccinating pregnant women or HCWs, or 150
whether an additional GP visit will be charged for these acts. Since this was unknown to the Belgian 151 program managers, both these options were evaluated. 152
Results
153
Pregnant women 154
The cost-effectiveness of increasing vaccine uptake in 2 nd or 3 rd term pregnant women depends on the 155 assumed vaccine administration cost and the degree of vaccine protection indirectly inferred to the new-156 born child. Increasing vaccine uptake is very likely to be cost-effective when there are no marginal 157 administration costs, or when these remain substantially lower than the current price for a GP 158 consultation. At marginal administration costs of 1 GP consult (€23.32), seasonal influenza vaccination of 159 pregnant women would only be cost-effective, if indirectly transferred vaccine protection to the child is 160 high (i.e. 100% in Figure 2 ). Figure S1 (in supplementary material) shows the variable importance, 161
indicating that the case-fatality ratio of the mother, vaccine efficacy and QALY loss are all influential. 162
Ignoring the life years lost due to the death of a foetus only has a minor impact on the cost-effectiveness 163 (median ICER of €6,706 instead of €6,616 per QALY gained). With a per-season median of 26 versus 3 164 hospitalisations prevented, the incremental health gains of the program are larger for the neonates than 165 for the pregnant women, respectively (see Table 2 ). The larger scope for prevented hospitalisations and 166 deaths in neonates is due to the high risks for neonates afflicted by ILI (mean proportion hospitalised 167 2.92%, based on the 0-4 year old age group Figure 3 , Table S1 in Supplementary material). 183
Probabilistic sensitivity analysis, assuming one secondary symptomatic influenza infection per 184 symptomatic infection in the target group, reveals that the uncertainties around the case-fatality ratio 185 for secondary cases and the vaccine efficacy exert the highest relative influence on QALYs gained and 186 consequently on the net benefits (see Figure S2 in supplementary material). This finding holds for the 187 different age groups of secondary cases. 188
We additionally investigated splitting up the group of HCWs according to age. Observed changes in ICER 189 values are minor, since differences in input variables between HCW age groups are small. 190
Persons with underlying illnesses 191
Increasing vaccine uptake in people with underlying illnesses is cost-effective for persons aged 50 and 192 older, for all life expectancies considered ( Figure 4 , uncertainty (see large impact of vaccine efficacy on the net benefit in Figure S1 in supplementary 237 material), together with the case-fatality and hospitalisation ratios. 238
The basic structure of our decision-analytic model is rather conservative. Firstly, for pregnant women 239 and people with underlying illnesses, herd immunity was not accounted for. Indeed, for these target 240 groups herd immunity is likely to be negligible, because they are not core transmitter groups in the 241 general population or in specific settings. Secondly, we assumed the vaccine would only protect for one 242 season against the circulating strains. However, it seems plausible that some vaccine recipients would 243 enjoy some residual protection into the next season, and that therefore this is also a conservative 244 assumption. Thirdly, we opted for a mean approach for the relative timings of vaccination of pregnant 245 women in relation to the onset of the influenza season and gestational age, based on previous seasons. 
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Tables and captions
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The hospitalisation rate of influenza cases seeking medical care (τ)
We randomize with equal probability between 3 scenarios:
We randomize with equal probability between 2 scenarios: For the age group over 65 years, we randomize with equal probability from the hospitalisation rates of the general population of that age (see reference)
[3]
The case fatality ratio of influenza cases seeking medical care (μ) Duration of symptoms for an ambulatory patient Gaussian (mean=6.43; sd=0.14)
[3] Full arrows indicate the causal structure of the model. Dashed arrows indicate how the group sizes were calculated, when it is different from the causal 305 structure, and how the sizes of the different groups were calculated using the input data available in Table 1 . F 1 = λ ILI * P influ ; F 2 = F 1 *(1-ε ); F 3 = 1/(1-P nomed ); F 4 = 306 1-μ-τ; P vac is the vaccination coverage of the target group; λ ILI is the yearly attack rate of influenza like illness (ILI) for which medical care is sought; P influ is the 307 proportion of influenza relative to the ILI cases seeking medical care; ε is the vaccine efficacy against influenza; τ is the influenza hospitalisation rate, μ the 308 influenza death rate and P nomed is the proportion of symptomatic influenza cases not seeking medical care (see also 
